ProQR Therapeutics NV has the GF Score of 44, which implies that the company
might have
Worst future performance potential, or not enough data.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Based on research and backtesting result, GuruFocus believes ProQR Therapeutics NV
might have
Worst future performance potential, or not enough data.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score
Performance Potential and All-in-One Screener Examples (1)
(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.
ProQR Therapeutics NV GF Score Related Terms
MEX:PRQRN vs GALT, HRTX, PLYX: GF Score Comparison
For the Biotechnology subindustry, ProQR Therapeutics NV's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ProQR Therapeutics NV GF Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ProQR Therapeutics NV's GF Score distribution charts can be found below:
* The bar in red indicates where ProQR Therapeutics NV's GF Score falls into.
ProQR Therapeutics NV (MEX:PRQRN) has a GF Score of 44 as of Jun. 25, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on ProQR Therapeutics NV and its competitors. This is 47% above median its historical median of 30.00. Over the past decade, ProQR Therapeutics NV's GF Score has ranged from 4.00 to 54.00.
Is ProQR Therapeutics NV's GF Score too high?
ProQR Therapeutics NV's current GF Score of 44 is 47% above median its 10-year median of 30.00. Over the past 10 years, this metric has ranged from a low of 4.00 to a high of 54.00. Overall, ProQR Therapeutics NV has a GF Score™ of 44/100, reflecting its overall financial health beyond just this single metric.
How does ProQR Therapeutics NV's GF Score compare to GALT and HRTX?
ProQR Therapeutics NV's GF Score of 44 can be compared against companies in the Biotechnology industry. Historically, ProQR Therapeutics NV's own GF Score has ranged from 4.00 to 54.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Biotechnology company?
A good GF Score depends on the Biotechnology industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on ProQR Therapeutics NV and its competitors. ProQR Therapeutics NV's current GF Score is 44, which is 47% above median its own 10-year median of 30.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ProQR Therapeutics NV stock overvalued right now?
ProQR Therapeutics NV (MEX:PRQRN) has a current GF Score of 44. The stock's GF Value™ is MXN40.07, compared to a current price of MXN36.00 — trading 10.2% below its estimated fair value. The current GF Score is 44, which is 47% above median its 10-year median of 30.00. ProQR Therapeutics NV's overall GF Score™ is 44/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For ProQR Therapeutics NV (MEX:PRQRN), the current GF Score is 44 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ProQR Therapeutics NV (MEX:PRQRN) Overvalued in 2026?
Based on GuruFocus' analysis, ProQR Therapeutics NV stock appears to be undervalued.
The current stock price of MXN36.00 is trading 10.2% below its estimated GF Value™ of MXN40.07.
Key valuation signals for MEX:PRQRN:
GF Score: 44 (47% above median its 10-year median of 30.00)
GF Value™: MXN40.07 vs. price of MXN36.00 (10.2% below fair value)
No single metric tells the full story. See the MEX:PRQRN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.
44GF Score
Get the complete analysis for MEX:PRQRN
GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:PRQRN has been successfully added to your 